

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166
---	-----------------------------------	---

Accreditation No: LAB 166

Awarded to

**Drugs Testing Laboratory, Punjab, Rawalpindi
Dhamyal Road, Hayal Sharif, Rawalpindi – Pakistan**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **27-12-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **26-12-2021**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

21-04-2021
Date

SD
Director General

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166
---	-----------------------------------	---

Testing Laboratory.

Accreditation Scope of Drugs Testing Laboratory, Punjab, Rawalpindi –
Pakistan

Permanent laboratory premises

Materials/ Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Paracetamol – Active Pharmaceutica l Ingredient	Pharmaceutical Testing	Quantitative Analysis/ Identification and Assay	Internal Method with reference to British Pharmacopoeia (BP) 2020 Volume # 3, Paracetamol Tablets Page # 1086
Ibuprofen - Active Pharmaceutica l Ingredient	Pharmaceutical Testing	Quantitative Analysis/ Identification and Assay	Internal Method with reference to United States Pharmacopoeia (USP) 2019 Volume # 1 Ibuprofen Tablets Page # 2235
Paracetamol Tablets	Pharmaceutical Testing	Disintegration	BP- 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Uniformity of Mass	BP- 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2020 Volume#3, Page#1086
Ibuprofen Tablets	Pharmaceutical Testing	Identification	USP- 2019, Volume#1, Page#2235
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 /USP 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#1, Page#2235

21-04-2021
Date

SD

Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166
---	-----------------------------------	---

Metformin Tablets	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2020, Volume#3, Page# 930-931
	Pharmaceutical Testing	Assay of Active Ingredients	Volume 2 USP2019 UV-Visible spectrophotometry Pg#2779
Atenolol Tablets	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	BP-2020, Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredient	British Pharmacopoeia (BP) 2020, Volume#3, Page#174
	Pharmaceutical Testing	Assay of Active Ingredient	Volume 1 USP2019 HPLC-UV Pg#403
Ciprofloxacin Tablets	Pharmaceutical Testing	Identification	USP-2019, Volume#1, Page#996
	Pharmaceutical Testing	Uniformity of Mass	BP- 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	BP- 2020 Appendix XII-A V-A384 – V-A388 / USP- 2019, Ch# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredient	USP- 2019, Volume#1, Page#997
	Pharmaceutical Testing	Assay of Active Ingredient	Volume 3 BP 2020 HPLC-UV Pg#364

21-04-2021
Date

SD

Director



**ACCREDITATION
DOCUMENT**

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 166

Amoxicillin Capsules	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#229
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#1, Page#229
Omeprazole Capsules	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#2, Page#3224
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#2, Page#3224
	Pharmaceutical Testing	Uniformity of Mass	BP- 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
Ciprofloxacin Injection	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#994
	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia (USP) 2019, Volume#1, Page#994
	Pharmaceutical Testing	Assay of Active Ingredient	Volume 3 BP 2020 HPLC-UV Pg#363
Amoxicillin for oral suspension	Pharmaceutical Testing	Assay of Active Ingredient	Volume 1 USP2019 HPLC-UV Pg#298
	Pharmaceutical Testing	pH	(USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS

21-04-2021
Date

SD
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166
---	-----------------------------------	---

Metronidazole Infusion	Pharmaceutical Testing	Assay of Active Ingredient	Volume 3 BP 2020 HPLC-UV Pg#953
	Pharmaceutical Testing	pH	(USP) 2019, Volume#4, Ch#791, Page#6948-6951 /MS
Metronidazole Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Glibenclamide Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Domperidone Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Diclofenac (film coated) Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Mefenamic acid Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Folic acid, ferrous fumarate Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Meloxicam Tablet	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Cetirizine Tablets	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Moxifloxacin Tablets	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Amlodipine Tablets	Pharmaceutical Testing	Weight Variation	Volume 5 BP 2020/ Consistency of formulated preparation/ Appendix XII-C
Carvedilol Tablets	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77

21-04-2021
Date

SD
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166
---	-----------------------------------	---

Losartan Tablets	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Atorvastatin Tablets	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Ramipril Tablets	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Prednisolone Tablets	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Flurbiprofen Tablet	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Diclofenac (enteric coated) Tablet	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Tramadol capsule	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#43
Chlorpheniramine Tablet	Pharmaceutical Testing	Disintegration	Volume 5 BP 2020/ Disintegration/ Appendix XII-A Volume 3 pg#77
Ceftriaxone Injection	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
Dexamethasone Sodium Injection	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
Dopamine Injection	Pharmaceutical Testing	pH	British Pharmacopoeia (BP) 2020, Volume#5, Appendix VI, V-A281 - V-A282 /MS
Naloxone Injection	Pharmaceutical Testing	pH	BP- 2020, Volume#5, Appendix VI, V-A281 - V-A282 /MS
Atracurium Injection	Pharmaceutical Testing	pH	USP- 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
Conductivity for Water for Injection	Pharmaceutical Testing	Conductivity	USP-2019, Volume#4, Chapter 6517, Page# 6799

21-04-2021
Date

SD
Director